HaasDWDes PrezRM. Mycobacterium tuberculosis. In: MandeliGLBennettJEDolinR, eds. Principles and practice of infectious disease. New York: Churchill Livingstone, 1995: 2213–43.
2.
Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep1989; 38: 236–8, 243–50.
3.
Initial therapy for tuberculosis in this era of multidrug resistance. Recommendations of the Advisory Committee for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep1993; 42 (RR-7): l–8.
4.
BarnesPFBarrowsSA. Tuberculosis in the 1990's. Ann Intern Med1993; 119: 400–10.
5.
IsemanM. Treatment of multidrug-resistant tuberculosis. N Engl J Med1993; 329: 784–91.
Management of persons exposed to multidrug resistant tuberculosis. MMWR Morb Mortal Wkly Rep1992; 41 (RR-11): 61–71.
8.
KohnoSKogaHKakuMMaesakiSHaraK. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest1993; 104: 1194–8.
9.
Garcia-RodriguezJAGarciaA Gomez. In-vitro activities of quinolones against mycobacteria. Br Soc Antimicrob Chemother1993; 32: 797–808.
10.
LombardiVJCataldo-CaputzalL. Ciprofloxacin susceptibility testing by MIC and disk elution of drug-resistant Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother1993; 32: 897–902.
11.
WeltmanACRoseDN. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. Arch Intern Med1994; 154: 2161–7.
12.
YewWWKwanSYMaWKKhinMAChauPY. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother1990; 26: 227–36.
13.
MohantyKCDhamgayeTM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest1993; 104: 1194–8.
HornDLHewlettDAlfallaCPetersonSOpalSM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis (letter). N Engl J Med1994; 330: 1241.
16.
HusseyGKibelMParkerN. Ciprofloxacin treatment of multiply drug-resistant extrapulmonary tuberculosis in a child. Pediatr Infect Dis J1992; 11: 408–9.
17.
YewWWPiddockUVLiMSKLyonDChanCYChengAFB. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother1994; 34: 343–51.
18.
RastogiNGohKS. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother1991; 35: 1933–6.
19.
NeumanM. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet1988; 14: 96–121.
20.
EasmonCSFCraneJPBlowerSA. Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. J Antimicrob Chemother1986; 18 (suppl D): 43–8.
21.
PeloquinCA. Pharmacology of the antimycobacterial drugs. Med Clin North Am1993; 77: 1253–62.
22.
American Thoracic Society/Centers for Disease Control. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med1994; 49: 1359–74.
23.
FriedenTRSterlingTPablos-MendezAKilburnJOCauthenGMDooleySW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med1993; 328: 521–6.
24.
FerebeeSH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc Med Thorac1970; 26: 28–106.
25.
IsemanMDSbarbaroJA, eds. National ACCP consensus conference on tuberculosis. Chest1985; 87 (suppl): S115–6.
26.
de CastellaH. Non-smoking: a feature of ulcerative colitis (letter). Br Med J1982; 284: 1706.
27.
RobertsCJDiggleR. Non-smoking: a feature of ulcerative colitis (letter). Br Med J1982; 285: 440.
28.
BuresJFixaBKomarkovaOFingerlandA. Non-smoking: a feature of ulcerative colitis (letter). Br Med J1982; 285: 440.
29.
SrivastavaEDRussellMAHFeyerabendCRhodesJ. Effect of ulcerative colitis and smoking on rectal blood flow. Gut1990; 31: 1021–4.
30.
LashnerBAHanauerSBSilversteinMD. Testing nicotine gum for ulcerative colitis patients: experience with single-patient trials. Dig Dis Sci1990; 35: 827–32.
31.
SrivastavaEDRussellMAHFeyerabendCWilliamsGTMastersonJGRhodesJ. Transdermal nicotine in active ulcerative colitis. Eur J Gastroenterol Hepatol1991; 3: 815–8.
32.
PullanRDRhodesJGaneshSManiVMorrisJSWilliamsGTTransdermal nicotine for active ulcerative colitis. N Engl J Med1994; 330: 811–5.
33.
ThomasGAORhodesJManiVWilliamsGTNewcombeRGRussellMAHTransdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med1995; 332: 988–92.
